Human IL-2 ELISpot Set

Contact us
Diaclone
Product Code: 856.001.015S
Product Group: ELISpot Kits
Supplier: Diaclone
CodeSizePrice
856.001.015S15 x 96 (sterile plates)£1,655.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Human
Regulatory Status: RUO
Application: ELISpot

Further Information

Additional 2:
Spots read visually or with reader
Cross reaction:
No cross reactivity with other human cytokines. Cross reactivity with simian IL-2.
Description:
Diaclone ELISpot Sets include capture and detection antibodies Streptavidin - Alkaline Phosphatase conjugated BSA BCIP/NTB blocking reagent.
Detection Target:
IL-2
Incubation:
3h after cell stimulation
Reactivity:
Human
Research Area:
Cytokines / Growth Factors
Specificity:
Recognizes natural human IL-2

References

  1. Dosset M. et al. Clin Cancer Res. 2012; 18(22): 6284-95 . Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor. https://www.ncbi.nlm.nih.gov/pubmed/23032748
  2. Kalogerakou F. et al.Hippokratia2008; 12(4): 230-5.. Detection of T cells secreting type 1 and type 2 cytokines in the peripheral blood of patients with oral lichen planus. https://www.ncbi.nlm.nih.gov/pubmed/19158967
  3. Montcuquet N. et al. Immunology2008;125(3): 320-30.. Regulatory T-cell expansion and function do not account for the impaired alloreactivity of ex vivo-expanded T cells. https://www.ncbi.nlm.nih.gov/pubmed/18445006
  4. Rinaldi M. et al.Thorax 2012; 10.1136/thoraxjnl-2011-200690. Antielastin B-cell and T-cell immunity in patients with chronic obstructive pulmonary disease. https://www.ncbi.nlm.nih.gov/pubmed/22442201
  5. Van Gulck E. R. et al J. Virol2008; 82(7): 3561-3573.. Efficient In Vitro Expansion of Human Immunodeficiency Virus (HIV)-Specific T-Cell Responses by gag mRNA-Electroporated Dendritic Cells from Treated and Untreated HIV Type 1-Infected Individuals. https://www.ncbi.nlm.nih.gov/pubmed/18234800
  6. Dosset M. et al. Clin Cancer Res. 2012; 18(22): 6284-95 . Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor. https://www.ncbi.nlm.nih.gov/pubmed/23032748
  7. Junwei W. et al. Cancer Cell Int.2016; 17: 10. . In vivo enhancement of the MAGE-specific cellular immune response by a recombinant MAGE1-MAGE3-TBHSP70 tumor vaccine. https://www.ncbi.nlm.nih.gov/pubmed/27330408